J Refract Surg. 2022 Feb;38(2):90-97. doi: 10.3928/1081597X-20211112-01. Epub 2022 Feb 1.
To compare small incision lenticule extraction (SMILE) and femtosecond laser-assisted in situ keratomileusis (FS-LASIK) in terms of the predictability of central stromal thickness reduction in eyes with high myopia.
In this prospective, randomized contralateral eye trial, 42 patients received SMILE in one eye and FS-LASIK (using the Amaris 750S excimer laser [SCHWIND eye-tech-solutions]) in the fellow eye for the correction of high myopia (manifest refraction spherical equivalent: < -6.00 diopters). Spectral-domain optical coherence tomography was used to measure the central corneal and epithelial thickness. Pre-operative and postoperative values were compared to determine the amount of central stromal reduction achieved.
At the 6-month follow-up visit, the amount of central stromal reduction was overestimated by 20.05 ± 5.92 µm in the SMILE group ( < .0001) and underestimated by 8.21 ± 8.14 µm in the FS-LASIK group ( < .0001). The mean actual central stromal reduction achieved with SMILE was significantly less than that achieved with FS-LASIK (10.10 ± 18.01 µm, range: 1.90 to 18.29 µm, < .001). The discrepancy between the planned and achieved central corneal stromal reduction was not associated with refractive overcorrection or undercorrection in either the SMILE group or the FS-LASIK group ( = .9743 vs = .0777).
In patients with high myopia, the laser software platform may underestimate and overestimate the amount of actual corneal reduction in eyes treated with FS-LASIK and SMILE, respectively. SMILE required less corneal stroma compared to FS-LASIK in the studied cohort using the Amaris 750S excimer laser when correcting a similar spherical equivalent refraction. .
比较小切口透镜提取术(SMILE)和飞秒激光辅助原位角膜磨镶术(FS-LASIK)在矫正高度近视眼中中央基质厚度减少的可预测性。
在这项前瞻性、随机对照的对侧眼试验中,42 名患者的一只眼接受 SMILE 治疗,另一只眼接受飞秒激光辅助原位角膜磨镶术(使用阿玛仕 750S 准分子激光[SCHWIND eye-tech-solutions])治疗,用于矫正高度近视(视力表屈光度等效球面镜:< -6.00 屈光度)。采用频域光相干断层扫描测量中央角膜和上皮厚度。比较术前和术后的值,以确定达到的中央基质减少量。
在 6 个月的随访中,SMILE 组中央基质减少量高估了 20.05 ± 5.92 µm( <.0001),FS-LASIK 组低估了 8.21 ± 8.14 µm( <.0001)。SMILE 组实际达到的平均中央基质减少量明显小于 FS-LASIK 组(10.10 ± 18.01 µm,范围:1.90 至 18.29 µm, <.001)。在 SMILE 组或 FS-LASIK 组中,计划的和实际的中央角膜基质减少量之间的差异与屈光过矫或欠矫无关( =.9743 对 =.0777)。
在高度近视患者中,激光软件平台可能分别低估和高估 FS-LASIK 和 SMILE 治疗的实际角膜减少量。在使用阿玛仕 750S 准分子激光治疗相似的等效球面镜屈光度时,SMILE 比 FS-LASIK 减少的角膜基质更少。